Vidora - Instructions For The Use Of Tablets, Reviews, Price, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Vidora

Vidora: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Vidora

ATX code: G03AA12

Active ingredient: ethinylestradiol (Ethinylestradiol) + drospirenone (Drospirenone)

Manufacturer: Laboratorios Leon Pharma S. A. (Laboratorios Leon Farma SA) (Spain)

Description and photo update: 2018-27-11

Prices in pharmacies: from 439 rubles.

Buy

Vidora is a combined oral contraceptive (COC).

Release form and composition

The drug is produced in the form of film-coated tablets: active tablets are yellow, round, biconvex, an almost white or white core stands out in the cross section; placebo tablets - white, round, biconvex, on a cross-section there is an almost white or white core [in a blister of 28 tablets (21 active + 7 placebo), in a carton box 1 or 3 blisters and instructions for use Vidora].

Composition of active tablets:

• active ingredients: drospirenone - 3 mg, ethinylestradiol - 0.03 mg;
• auxiliary components: corn starch, pregelatinized corn starch, povidone K30, crospovidone (Plasdone XL), crospovidone (povidone XL10), lactose monohydrate, magnesium stearate, polysorbate;
• composition of the film shell: opadry II yellow (titanium dioxide, talc, macrogol 3350, partially hydrolyzed polyvinyl alcohol, yellow iron oxide dye).

Placebo pills:

• auxiliary components: magnesium stearate, K30 povidone, anhydrous lactose;
• composition of the film shell: opadry II white (titanium dioxide, talc, macrogol 3350, partially hydrolyzed polyvinyl alcohol).

Pharmacological properties

Pharmacodynamics

Vidora is an oral low-dose combined monophasic hormonal contraceptive, which contains drospirenone (gestagen) and ethinyl estradiol (synthetic estrogen) as active substances.

The contraceptive effect is due to the interaction of several factors, among which the most important are: the ability of the drug to inhibit ovulation and increase the viscosity of the cervical secretion, as a result of which it becomes impermeable to sperm.

Provided that Vidora is used correctly, the Pearl index (an indicator reflecting the number of pregnancies in 100 women taking the drug during the year) is less than 1. The index may increase with improper intake or missed pills.

Drospirenone in a therapeutic dose also has an antiandrogenic and weak antimineralocorticoid effect. This substance does not have glucocorticoid, antiglucocorticoid and estrogenic activity, while it has a pharmacological profile similar to that of natural progesterone.

Due to its antiandrogenic activity, drospirenone reduces the production of sebum and improves the clinical course of acne (acne vulgaris). This should be considered when choosing a contraceptive, especially for women with acne, seborrhea and hormone-dependent fluid retention.

Thanks to the combination of drospirenone + ethinyl estradiol, Vidora improves the lipid profile and increases the concentration of high density lipoproteins.

The drug regulates menstrual bleeding: reduces the severity of pain, as well as the volume of discharge, thereby reducing one of the risk factors for the development of iron deficiency anemia. In addition, there is evidence that COCs reduce the risk of ovarian and endometrial cancer.

Pharmacokinetics

Drospirenone

Once in the gastrointestinal tract, the substance is absorbed quickly and almost completely. After a single oral administration, Cmax (maximum plasma concentration) is reached in 1-2 hours and is approximately 35 ng / ml. Bioavailability does not depend on food intake and is 76–85%.

Drospirenone binds to plasma albumin, does not bind to sex hormone binding globulin (SHBG) and to corticosteroid binding globulin (CSG). The serum concentration of free drospirenone is not more than 5% of the dose taken. The increase in SHBG induced by estradiol does not affect the binding of drospirenone to plasma proteins. The apparent volume of distribution is on average 3.7 ± 1.2 l / kg.

The equilibrium plasma concentration is approximately 60 ng / ml and is achieved between 7 and 14 days from the start of Vidora. A further increase in concentration is noted between the first and sixth cycle of taking the drug; there is no subsequent increase in concentration.

Drospirenone is almost completely metabolized in the liver. The cytochrome P450 system practically does not participate in the biotransformation of the drug. The metabolites of the substance in the blood plasma are mainly represented by its acidic forms, which are formed due to the rupture of the lactone ring, as well as 4,5-dihydro-drospirenone-3-sulfate.

The metabolic clearance rate is 1.5 ± 0.2 ml / min / kg. The half-life is ~ 40 hours. The metabolites are excreted through the intestine and by the kidneys in a ratio of 1.2 ÷ 1.4.

Pharmacokinetics of drospirenone in special cases:

• renal failure: with mild renal failure (creatinine clearance 50–80 ml / min), the equilibrium concentration is comparable to that in women with normal renal function. In moderate renal failure (creatinine clearance 30–50 ml / min), the plasma concentration of the substance is approximately 37% higher than in healthy volunteers;
• hepatic impairment: in case of moderate hepatic function impairment (class B on the Child-Pugh scale), the area under the concentration-time pharmacokinetic curve is comparable to that in healthy women with similar maximum concentrations in the absorption and distribution phases. The half-life in patients with moderate hepatic dysfunction is 1.8 times higher than in healthy volunteers, while the clearance of drospirenone is reduced by about 50%. In severe hepatic impairment, pharmacokinetics have not been studied.

Ethinylestradiol

Once in the gastrointestinal tract, the substance is rapidly and almost completely absorbed. After a single dose, the maximum plasma concentration is achieved within 1–2 hours and is 88–100 ng / ml. Ethinyl estradiol is metabolized during absorption and during the first passage through the liver. The absolute bioavailability is 60%, simultaneous food intake reduces this indicator in about 25% of cases.

The substance binds to plasma proteins at a level of ~ 98.5%. Apparent volume of distribution (V _d) ~ 5 l / kg.

Equilibrium plasma concentration is achieved during the second half of the cycle of taking Vidora.

Ethinylestradiol is an inducer of SHBG synthesis in the liver.

Approximately 50-60% of the dose undergoes presystemic conjugation in the mucous membrane of the small intestine and liver (first-pass effect). The substance is metabolized mainly by aromatic hydroxylation, as a result of which methylated and hydroxylated metabolites are formed (free, as well as in the form of conjugates with sulfuric and / or glucuronic acid). Part of the ethinyl estradiol conjugated with glucuronic acid undergoes enterohepatic recirculation (i.e., reabsorption in the intestine after excretion in the bile).

Ethinylestradiol is completely metabolized (practically not excreted unchanged). The metabolic clearance rate from plasma is 5 ml / min / kg. Metabolites are excreted through the intestines and kidneys in a ratio of 6 ÷ 4.

The half-life is approximately 24 hours.

Indications for use

Vidora is intended for oral contraception.

Contraindications

Absolute:

• hormone-dependent malignant diseases (including tumors of the genital organs or breast) or suspicion of their presence;
• unexplained genesis of vaginal bleeding;
• diabetes mellitus with concomitant diabetic angiopathy;
• lactase deficiency, hereditary lactose intolerance, glucose-galactose malabsorption syndrome;
• migraine with focal neurological symptoms, including a history;
• severe liver disease and moderate liver failure (Vidora can be used no earlier than three months after the normalization of the indicators of functional liver tests);
• severe / acute renal failure;
• pancreatitis with severe hypertriglyceridemia, including a history;
• benign / malignant liver tumors, including a history;
• conditions that may precede thrombosis (for example, angina pectoris, atrial fibrillation, transient ischemic attacks), including a history;
• venous and arterial thrombosis (for example, cerebrovascular disorders, pulmonary thromboembolism, deep vein thrombosis, myocardial infarction), including a history;
• hereditary or acquired predisposition to venous or arterial thrombosis (eg, antithrombin III deficiency, protein S or protein C deficiency, hyperhomocysteinemia, the presence of antiphospholipid antibodies in the body, resistance to activated protein C);
• severe or multiple risk factors for the development of venous / arterial thrombosis, such as diseases of the coronary arteries or cerebral vessels, uncontrolled arterial hypertension, complicated lesions of the valvular apparatus of the heart, atrial fibrillation, prolonged immobilization, any surgical interventions on the lower extremities, volumetric surgical interventions, extensive trauma, smoking over the age of 35, obesity (body mass index> 30 kg / m ²);
• pregnancy or suspicion of its presence;
• period of breastfeeding (lactation);
• hypersensitivity to any of the components of Vidora.

If any of the listed diseases / conditions develops for the first time while taking COCs, the drug should be discontinued immediately.

Relative (Vidora should be used with extreme caution due to the risk of complications):

• hypertriglyceridemia;
• diseases in which peripheral circulatory disorders can occur, such as systemic lupus erythematosus, diabetes mellitus without vascular disorders, phlebitis of superficial veins, sickle cell anemia, ulcerative colitis, Crohn's disease, hemolytic uremic syndrome;
• hereditary angioedema;
• mild to moderate liver disease;
• diseases that first appeared or worsened during a previous pregnancy or during the period of previous use of sex hormones, such as herpes of pregnancy, chloasma, Sydenham's chorea, porphyria, otosclerosis with hearing impairment, cholelithiasis, jaundice and / or itching associated with cholestasis;
• Thrombosis risk factors for thromboembolism: smoking, age over 35 years, non-smoking women, obesity with a body mass index less than 30 kg / m ², migraine without focal neurological symptoms, dislipoproteinemia, uncomplicated defects valvular controlled hypertension, the presence of thromboembolism / family history of thrombosis (cerebrovascular accident, myocardial infarction or thrombosis at a young age in one of the closest relatives).

Vidora, instructions for use: method and dosage

Vidor tablets are indicated for oral administration. They should be swallowed whole, without breaking or chewing, drinking plenty of water.

The drug should be taken 1 tablet once a day (at about the same time of day) for 28 consecutive days in the order indicated on the blister pack, starting with active tablets (yellow) and ending with placebo tablets (white).

When taking placebo pills (2-3 days after taking the last active pill), menstrual bleeding is observed, which may not end until the start of a new package.

Taking pills from each subsequent new package must be started without interruption, that is, the next day after taking the last inactive tablet from the previous package.

If during the previous month the woman has not taken another contraceptive, Vidor tablets should be started on the first day of the menstrual cycle (i.e., on the first day of menstruation). You can start taking it on days 2-5, but in this case, an additional method of contraception (condoms) must be used within 7 days.

Recommendations for starting taking Vidora in other cases:

• switching from another COC: for preparations containing 21 tablets / pills in a package - the next day after taking the last active pill / pill, but no later than the next day after the usual 7-day break; for preparations containing 28 tablets / pills in a package - the next day after taking the last inactive pill / pill;
• switching from a transdermal patch, vaginal ring: on the day of their removal, but no later than the day when a new patch should be glued or a new ring inserted;
• switching from hormonal contraceptives containing only gestagen (“mini-pills”, injectable forms, subcutaneous implants, controlled-release intrauterine systems): “mini-pills” - any day without interruption; implant and intrauterine system - on the day of their removal; injectable form - on the day when you need to do the next injection. In all these cases, during the first 7 days of taking Vidora, you must additionally use barrier contraception;
• abortion in the first trimester of pregnancy: on the day of termination of pregnancy (additional contraceptive protection is not required in this case);
• abortion in the second trimester of pregnancy and childbirth (in the absence of breastfeeding): on days 21–28, then additional protection is not required. You can start taking it later, but then during the first 7 days it is necessary to use barrier contraceptives.

Options for changing the day of the onset of menstrual bleeding:

• skip the placebo tablets from the current package and start taking the active tablets from the new package. So you can extend the cycle for any period, but no more than 21 days, that is, until the end of the active tablets from the second package. At this time, spotting or breakthrough bleeding is possible. Regular use of Vidora should be resumed after the end of taking all pills (including inactive ones) from the second package;
• reduce the duration of taking inactive tablets for the required number of days. The shorter the interval, the higher the likelihood of no withdrawal bleeding and the appearance of spotting discharge and breakthrough bleeding while taking the drug from the second package.

Taking a pill in case of a pass

If a woman forgets to take a placebo pill, no action is required. The missed pills should be discarded to avoid accidentally extending the usual break for more than 7 days.

If you miss taking an active pill, if the delay is less than 12 hours, the contraceptive effect of Vidora does not decrease. A woman should take the missed pill as soon as possible, then adhere to the usual regimen.

If the delay is more than 12 hours, the contraceptive effectiveness of Vidora may decrease (since more than 36 hours pass from the moment of taking the last pill). The more pills are missed in a row, and the closer the pass is to the usual 7-day break, the higher the risk of pregnancy, since 7 days of continuous COC use are required to achieve an adequate contraceptive effect (suppression of the hypothalamic-pituitary-ovarian system). The decision in such a situation depends on the week in which the woman forgot to take the pill:

• 1 week of the cycle: you should take the missed pill as soon as possible, even if you have to immediately take 2 pills, then adhere to the usual regimen and additionally use barrier contraceptives for 7 days. If during the week preceding the missed appointment, there was intercourse, pregnancy is possible;
• 2 week of the cycle: you should take the missed pill as soon as possible, even if you have to immediately take 2 pills, then adhere to the usual regimen. If during the previous 7 days the woman strictly adhered to the recommendations for the use of Vidora, additional barrier contraception is not required. Otherwise, as well as if you miss two or more pills within the next 7 days, additional contraceptive protection is required;
• 3 week of the cycle: you should take the missed pill as soon as possible, even if you have to immediately take 2 pills (but not more than two, even if you miss several doses), then adhere to the usual regimen until the end of the active pills from the current package. Discard the inactive pills and start taking the active pills from the new package, i.e. you do not need to take the usual 7-day break. For the next 7 days, you must additionally use a barrier method of contraception. Until the end of the tablets from the second package, menstrual bleeding will most likely be absent, but spotting bleeding or uterine bleeding may occur on the days of taking the drug from the second package. If the woman does not have withdrawal bleeding while taking the placebo tablets, pregnancy should be excluded.

The absorption of the active substances of Vidora may be impaired in severe gastrointestinal disorders. In this connection, additional contraceptive measures are required. If diarrhea or vomiting occurs within 4 hours after taking the active tablet, you must adhere to the recommendations given for taking the missed tablets. If the woman does not want to change the usual dosage regimen and postpone the onset of withdrawal bleeding to another day, the additional active pill can be taken from a different package.

Side effects

A scale for assessing the incidence of side effects: often - not less than 1/100, but less than 1/10; infrequently - not less than 1/1000, but less than 1/100; rarely - not less than 1/10 000, but less than 1/1000.

Possible adverse reactions:

• on the part of the cardiovascular system: infrequently - an increase or decrease in blood pressure; rarely - arterial / venous thromboembolism (manifested by the following nosological forms of the disease: peripheral deep vein occlusion, thrombosis and thromboembolism / pulmonary vascular occlusion, thrombosis, thromboembolism and infarction / myocardial infarction / cerebral infarction and stroke);
• from the central nervous system: often - headache / migraine pain;
• from the digestive system: often - nausea; infrequently - vomiting, diarrhea;
• from the immune system: rarely - hypersensitivity reactions, bronchial asthma; with hereditary angioedema - the development or aggravation of symptoms;
• on the part of the organ of hearing and balance: rarely - hearing loss;
• from the skin and subcutaneous tissues: infrequently - alopecia, eczema, acne, itching; rarely - erythema nodosum, erythema multiforme;
• from the reproductive system and mammary glands: often - vaginal discharge, menstrual irregularities, breast tenderness, intermenstrual bleeding, vulvovaginal candidiasis; infrequently - an increase in the mammary glands, colpitis, decreased / loss of libido; rarely - discharge from the mammary glands;
• others: infrequently - fluid retention in the body, decrease or increase in body weight.

The following side effects have been reported in women taking COCs with delayed symptoms or in very rare cases and, presumably, may be caused by taking hormonal contraceptives: liver dysfunction, liver tumors (benign and malignant), ulcerative colitis, Crohn's disease, pancreatitis in women with hypertriglyceridemia, changes in glucose tolerance and the development of insulin resistance, breast cancer.

The relationship between the development or worsening of the following diseases with the use of COCs has not been reliably established, but it is possible: herpes during pregnancy, systemic lupus erythematosus, epilepsy, porphyria, hemolytic uremic syndrome, Sydenham's chorea, uterine fibroids, cholelithiasis, cholestatic jaundice and / or itching, associated with cholestasis.

Overdose

In case of an overdose of Vidora, the following symptoms may occur: metrorrhagia or spotting spotting from the vagina, nausea and / or vomiting.

The drug has no specific antidote, the treatment is symptomatic.

special instructions

Prescription of Vidora as a hormonal contraceptive is especially useful for women who have seborrhea, acne (acne) or hormone-dependent fluid retention.

Before taking Vidora, it is necessary to exclude pregnancy and disorders of the blood coagulation system. It is also recommended to undergo a thorough gynecological and general medical examination, including a cytological examination of the cervix and examination of the mammary glands. If a woman has been taking COCs for a long time, preventive follow-up examinations should be taken at least once every six months.

Like any other contraceptive, Vidora does not protect against infection with sexually transmitted infections. Every patient must be warned about this.

The contraceptive efficacy of the drug may decrease if pills are missed, diarrhea and vomiting, as well as with the simultaneous use of certain drugs.

While taking Vidora, irregular bleeding is possible (spotting spotting or breakthrough bleeding), especially in the first months of COC use. For this reason, it makes sense to assess any irregular bleeding no earlier than 3-4 months of regular contraception.

In cases where irregular bleeding recurs or develops for the first time after regular previous cycles, it is recommended to conduct a thorough examination to exclude pregnancy and malignant neoplasms.

Some women do not develop withdrawal bleeding during the usual 7-day break. If the patient did not violate the rules for taking Vidora, pregnancy is unlikely. However, in cases where there have been irregularities, or there is no menstrual bleeding for two months in a row, it is recommended to exclude pregnancy from the next package before taking the drug.

Some epidemiological studies have reported an increased risk of cervical cancer in patients taking long-term COCs. However, this connection has not been reliably proven.

54 epidemiological studies using a meta-analysis examined the risks of COCs in relation to the development of breast cancer. Women who were taking oral contraceptives at the time of the study showed a relatively increased risk of this disease (RR = 1.24), but the relationship with hormonal drugs has not been proven. The increased risk could be due to an earlier diagnosis of cancer (since women taking COCs are more likely to be examined by a doctor), the biological effects of COCs, or a combination of both factors.

Women prone to developing chloasma are advised to avoid prolonged exposure to ultraviolet radiation and sun exposure.

COCs can worsen the course of epilepsy and endogenous depression.

Drospirenone, having antimineralocorticoid activity, increases the concentration of aldosterone and renin in blood plasma.

Vidora can affect the biochemical parameters of renal, adrenal, liver and thyroid function, as well as the amount of plasma transport proteins such as lipid / lipoprotein fractions, corticosteroid-binding globulin, fibrinolysis, blood clotting and carbohydrate metabolism. Typically, these changes are within the normal range.

There is no need to adjust the dose of insulin and oral hypoglycemic drugs in diabetes mellitus, but the patient's condition should be monitored, since insulin resistance and the development of glucose tolerance may change with the use of combined oral contraceptives.

If a persistent, clinically significant increase in blood pressure develops, Vidor should be canceled and a doctor consulted. After normalization of blood pressure through adequate antihypertensive therapy, COC intake can be resumed.

Liver tumors were diagnosed in some women while taking COCs. This should be taken into account when carrying out differential diagnostics in patients with severe pain in the abdominal region, signs of intra-abdominal bleeding, enlarged liver.

In the course of epidemiological studies in women receiving COCs, an increase in the incidence of arterial and venous thrombosis and thromboembolism was found. The greatest risk of their development is in the first year of taking the contraceptive (especially in the first 3 months) and when you resume taking it after a 4-week break.

The approximate incidence of venous thromboembolism (VTE) in women taking COCs with a low estrogen content (<0.05 mg) is no more than 4 cases out of 10,000 per year (in women who do not take oral contraceptives, this indicator ranges from 0, 5 to 3 in 10,000).

For drugs containing drospirenone, the risk of thromboembolic complications is approximately 2 times higher than for drugs containing norgestimate, levonorgestrel, or norethindrone. The doctor recommending Vidor must warn the patient about this. The incidence of VTE in women taking COCs with drospirenone is approximately 9-12 per 10,000 within 1 year (with levonorgestrel - 5-7 per 10,000). However, the incidence of VTE while taking COCs is less than that during pregnancy.

There are very rare cases of development in women receiving COCs, thrombosis of other blood vessels, for example, mesenteric, hepatic, central retinal vein and its branches, renal arteries and veins. However, their relationship with the use of oral contraceptives has not been established.

Women should be warned to cancel Vidor and consult a doctor if any symptoms appear that may indicate the development of arterial or venous thrombosis. These include: one-sided pain and / or swelling of the lower extremities, sudden severe chest pain (including radiating to the left arm), sudden cough, sudden shortness of breath, weakness, or very significant sudden loss of sensation on one side or in one part of the body, any unusual, severe and / or prolonged headache, increased severity and frequency of migraine, dizziness, diplopia, sudden partial or complete loss of vision, aphasia or slurred speech, movement disorders, loss of consciousness or fainting (including with an epileptic seizure), symptom complex "acute abdomen".

The risk of thrombosis and thromboembolism increases in the following cases: aggravated family history (the presence of thromboembolic complications in close relatives at a relatively young age), age over 35, smoking (and the risk increases in the future as the age and / or the number of cigarettes smoked), obesity, dyslipoproteinemia, arterial hypertension, atrial fibrillation, heart valve disease, temporary immobilization (including air travel for 4 hours or more), prolonged immobilization, major surgery, any operation on the lower limbs, or major trauma. Patients who are indicated for elective surgery should stop taking Vidora in 4 weeks; the drug can be resumed no earlier than 2 weeks after the end of the immobilization period.

The risk of thromboembolism is increased postpartum. Peripheral circulation disorders are also possible in chronic inflammatory bowel diseases (Crohn's disease and ulcerative colitis), hemolytic uremic syndrome, diabetes mellitus, sickle cell anemia, and systemic lupus erythematosus.

If the severity or frequency of migraine increases while taking COCs, discontinuation of the drug should be considered.

The following biochemical parameters can be a sign of a hereditary or acquired predisposition to venous or arterial thrombosis: antiphospholipid antibodies (lupus anticoagulant, antibodies to cardiolipin), antithrombin III deficiency, hyperhomocysteinemia, resistance to APS, deficiency of proteins C and S.

When assessing the balance of benefits and risks, the doctor should take into account that adequate treatment of the above diseases can reduce the likelihood of developing thrombosis associated with them. In addition, the risk of thrombosis during pregnancy is higher than with COCs.

Influence on the ability to drive vehicles and complex mechanisms

No negative influence of Vidora's components on cognitive and psychomotor functions of a person was revealed.

Application during pregnancy and lactation

Oral contraceptives are contraindicated during pregnancy.

Vidor should be canceled immediately if a pregnancy is diagnosed while it is being taken.

Extensive epidemiological studies have not established an increased risk of developing developmental defects in children whose mothers received sex hormones before pregnancy. Also, the teratogenic effect of the drug was not revealed if it was inadvertently taken in the early stages of pregnancy.

Information on the use of a combination of drospirenone + ethinylestradiol during pregnancy is limited, therefore it is not possible to draw definite conclusions about the effect of Vidora on the course of pregnancy, the development of the fetus and the newborn child. There are no significant epidemiological data to date.

For women who are breastfeeding, it is contraindicated to take Vidora as a contraceptive, since sex hormones and / or their metabolites can penetrate into breast milk in small quantities, and also change its composition and amount.

Pediatric use

Vidora can be prescribed to girls from the moment of reaching puberty (after the onset of menarche). No dose adjustment is required.

With impaired renal function

In renal insufficiency of mild and moderate severity, the negative effect of Vidora was not revealed. However, in the first cycle of taking the drug, especially with the simultaneous use of potassium-sparing agents, the concentration of potassium in the blood plasma should be monitored.

Vidor is contraindicated in severe or acute renal failure.

For violations of liver function

In case of mild and moderate hepatic insufficiency (class B according to the Child-Pugh classification), the negative effect of Vidora was not revealed.

It is contraindicated to take COCs for severe liver diseases (until functional liver function tests are normalized), as well as for benign and malignant liver tumors at the present time or in history.

Use in the elderly

Vidora is intended to prevent unwanted pregnancies and is therefore not used after menopause.

Drug interactions

The contraceptive efficacy of Vidors is reduced by tetracycline and penicillin antibiotics. During their use and within 7 days after cancellation, an additional barrier method of contraception should be used.

Long-term use of drugs-inducers of microsomal enzymes in the liver can lead to a decrease in contraceptive protection, since they increase the clearance of sex hormones and, as a result, reduce their effect. Such drugs include: St. John's wort, barbiturates, griseofulvin, rifabutin, oxcarbazepine, topiramate, carbamazepine, felbamate, phenytoin, rifampicin, primidone. HIV protease inhibitors (eg ritonavir), non-nucleoside reverse transcriptase inhibitors (eg nevirapine), and combinations thereof, also have the potential to affect hepatic metabolism. For this reason, with the concomitant administration of drugs that affect the induction of microsomal liver enzymes, and within 28 days after their cancellation, a barrier method of contraception should be additionally used. If you need to continue taking these drugs after taking the last active Vidor tablet from the current package, you need to skip taking the placebo tablets and start taking the active tablets from the new package.

Vidora can affect the metabolism of other concurrently used drugs, due to which their concentrations in plasma and tissues decrease (for example, lamotrigine) or increase (for example, cyclosporine).

It is assumed that COCs can increase the concentration of potassium in the blood plasma in patients receiving simultaneously drugs that increase the plasma level of potassium, such as potassium-sparing diuretics, angiotensin II receptor antagonists, aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors (anti-inflammatory drugs), some nonsteroidal for example, indomethacin). However, in a study of the interaction of a combination of drospirenone + ethinyl estradiol with an ACE inhibitor in women with moderate arterial hypertension in the enalapril and placebo groups, there was no significant difference between serum potassium concentrations.

Drospirenone is metabolized without the participation of the cytochrome P450 system, therefore inhibitors of this enzyme system do not affect the metabolism of the drug.

In studies of in vitro inhibition and drug interaction in vivo, in which healthy female volunteers took part, it was found that in a daily dose of 3 mg drospirenone does not affect the metabolism of midazolam, simvastatin and omeprazole.

COCs affect glucose tolerance and can alter peripheral insulin resistance, however, correction of oral hypoglycemic drugs is not required.

Analogs

Vidora's counterparts are Angeletta, Benidetta, Benidetta mini, Vezantra, Vidora micro, Daisy-30, Delsia, Dieziklen, Klayra, Melleva, Modelle pro, Modelle trend, Modelle liberal, Modelle ovule, NovaRing, Femiss Ginesta, Jamera, etc.

Terms and conditions of storage

Store at temperatures up to 30 ° C out of reach of children.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Vidor

Vidora is a cheaper analogue of such well-known contraceptives as Yarina and Jess. Doctors prescribe it primarily as a contraceptive, but it is also used in the treatment of hyperandrogenism syndrome and polycystic ovary syndrome.

In positive reviews about Vidor, women note such positive effects as normalization of the menstrual cycle and a decrease in the severity of premenstrual syndrome. The antiandrogenic effect of the drug is highly appreciated by patients with acne or seborrhea. The contraceptive does not increase body weight, and sometimes, on the contrary, contributes to some weight loss. Despite the large list of possible side effects, Vidora is well tolerated. Slightly pronounced adverse reactions are usually noted only at the beginning of the intake, after which they disappear. Most often there are: headache, engorgement of the mammary glands, mood swings, drowsiness, nausea.

However, there are reports where women describe the development of severe side effects, due to which they had to stop taking Vidora. These include: significant mood swings, chest pain, severe headache, abdominal pain, vomiting.

Price for Vidoru in pharmacies

Depending on the pharmacy chain in which the drug is sold, the price for Vidoru is approximately 530-675 rubles. per pack of 28 tablets (21 + 7).

Vidora: prices in online pharmacies

Drug name Price Pharmacy

Vidora set of tablets film-coated tablets 28 pcs. 439 r Buy

Vidora micro 3 mg + 0.02 mg film-coated tablets 21 + 7 28 pcs. 454 RUB Buy

Reviews Vidor micro 454 RUB Buy

Vidora micro 3 mg + 0.02 mg film-coated tablets 24 + 4 28 pcs. 458 r Buy

Reviews Vidor micro 458 r Buy

Vidora Micro tablets p.o. 3mg + 0.02mg 28 pcs. 548 RUB Buy

Vidora Micro tablets p.o. 3.0mg + 0.02mg 28 pcs. RUB 600 Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!